30. Consolidated companies as of 31 December 2019
Name of the subsidiary |
Country |
% voting right |
Change in % voting |
|---|---|---|---|
Biofocus DPI AG in liquidation |
Switzerland |
100% |
|
Galapagos Biopharma Belgium BV |
Belgium |
100% |
100% |
Galapagos Biopharma Netherlands B.V. |
The Netherlands |
100% |
100% |
Galapagos Biopharma Spain S.L.U |
Spain |
100% |
100% |
Galapagos Biopharma Italy S.r.l. |
Italy |
100% |
100% |
Galapagos Biopharma Germany GmbH |
Germany |
100% |
100% |
Galapagos Biotech Ltd. |
United Kingdom |
100% |
|
Galapagos BV |
The Netherlands |
100% |
|
Galapagos GmbH |
Switzerland |
100% |
|
Galapagos, Inc. |
United States |
100% |
|
Galapagos NV |
Belgium |
Parent company |
|
Galapagos Real Estate 1 BV |
Belgium |
100% |
|
Galapagos Real Estate 2 BV |
Belgium |
100% |
|
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
100% |
Galapagos SASU |
France |
100% |
|
Fidelta d.o.o. |
Croatia |
100% |
|
Xenometrix, Inc. in liquidation |
United States |
100% |
|
In the course of 2019 we incorporated the following new legal entities: Galapagos Biopharma Belgium BV (Mechelen, Belgium), Galapagos Biopharma Netherlands B.V. and Galapagos Real Estate Netherlands B.V. (Leiden, the Netherlands); Galapagos Biopharma Germany GmbH (München, Germany); Galapagos Biopharma Spain S.L.U. (Madrid, Spain) and Galapagos Biopharma Italy S.r.l. (Milan, Italy).
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.